Quantcast
Last updated on April 24, 2014 at 10:45 EDT

Latest LRRK2 Stories

2014-03-26 12:28:27

Biomedical research institute appoints two key positions, expanding its impact on neurodegenerative science GRAND RAPIDS, Mich., March 26, 2014 /PRNewswire/ -- Van Andel Research Institute's Center for Neurodegenerative Science continues to expand its research portfolio and increase its impact in the field of Parkinson's disease research. The Center recently appointed Dr. Jiyan Ma, whose laboratory studies prions, the misfolded proteins associated with many contagious...

2014-02-25 08:33:01

NEW YORK, Feb. 25, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson's disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants -- people with or at risk to develop Parkinson's -- will lead to...

2014-01-08 17:05:18

Gladstone findings challenge conventional wisdom; point to new therapeutic strategies The most devastating aspect of Parkinson's disease may not be its debilitating symptoms, which rob its victims of their ability to control their own movement. It may not be the millions around the world and their families who suffer each day from the disease's harmful effects. Instead, it may in fact be that its root causes remain largely a mystery. But now, scientists at the Gladstone Institutes have...

2013-11-20 04:21:31

Collaborative Effort to Further Validate Genetic Variants SUNNYVALE, Calif. and MELVILLE, N.Y., Nov. 20, 2013 /PRNewswire-USNewswire/ -- The Parkinson's Institute and Clinical Center announced today that they, in partnership with Population Diagnostics, Inc., have discovered a number of new genes relevant to the cause of Parkinson's disease. The innovative approach used for this study focuses first on genome-wide investigation of gene copy number variants (CNVs) followed by targeted...

2013-07-17 12:27:45

NEW YORK, July 17, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced that qualified researchers may now request access to clinical data and biospecimens from a collection of studies exploring promising areas in Parkinson's research. The Foundation is also offering funding for use and analysis of the available information and materials to progress therapeutic and disease-modifying treatments. "The standardized collection of...

2013-07-15 12:26:33

Michael J. Fox Foundation sponsored study seeks people in San Diego area without Parkinson's disease to participate in landmark biomarker study SAN DIEGO, July 15, 2013 /PRNewswire-USNewswire/ -- University of California, San Diego School of Medicine will be one of 23 official clinical sites of the Parkinson's Progression Markers Initiative's (PPMI) new arm to study at-risk populations for Parkinson's disease (PD). The $55 million landmark observational clinical study launched in...

2013-05-08 12:29:25

NEW YORK, May 8, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) is today announcing the launch of three new funding programs focused on driving research toward transformative treatments and a cure for Parkinson's disease (PD). Two programs will promote critical work on the promising therapeutic targets LRRK2 and Parkin. A third program allows researchers to propose developing biomarkers of cognitive impairment in PD. The new funding opportunities are open to...

2013-04-23 12:33:14

--Study completes enrollment of original 600-member cohort; infrastructure and open-source model are transforming biomarker research-- NEW YORK, April 23, 2013 /PRNewswire-USNewswire/ -- The Parkinson's Progression Markers Initiative (PPMI), a landmark biomarker clinical study, has completed enrollment of its initial 600-member cohort of Parkinson's patients and controls, and will launch additional study cohorts to leverage the existing PPMI infrastructure and evaluate multiple...

2013-03-18 10:56:41

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology (AAN), March 16-23, 2013, in San Diego. For additional information, or to arrange an interview, please contact Karin Eskenazi at 212-342-0508 or ket2116@columbia.edu, or Christina Stolfo at 212-305-5587 or chs9135@nyp.org ORAL PRESENTATIONS Deoxypyrimidine Monophosphates Treatment for Thymidine Kinase 2...

2013-03-04 11:17:30

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells. The study, which published online today in the journal Nature Neuroscience, could also open up treatment possibilities for both familial Parkinson's and the more common form of Parkinson's that is not inherited. Parkinson's disease is a gradually progressing disorder of the nervous system that causes stiffness or...